Egypt

Egypt appears to have a restrictive controlled-substances environment: non-medical possession, use, manufacture, import and export of narcotic/psychotropic drugs are criminalised under the country's drug-control framework, while controlled medical and scientific use remains the relevant lawful pathway. This means any psychedelic access is likely limited to approved research or tightly regulated hospital use, not a retail or general prescribing market.

Key Insights

A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Egypt.

1
Blossom's Egyptian trial profile is ketamine-led and depression-focused, suggesting local activity is concentrated in anaesthetic or antidepressant-adjacent research rather than classic psychedelic therapy.
2
The regulatory environment looks permissive only for controlled medical/scientific use, and restrictive for general access, so any future psychedelic work would likely need a formal ethics, import and drug-control pathway.
3
Recent UNODC materials indicate Egypt continues to update its controlled-substances list by decree, which implies the scheduling environment can change without broad public-facing reform.
4
The presence of ketamine publications from Cairo University, Al-Azhar University and other Egyptian institutions suggests the clinical ecosystem exists, but mostly in conventional medical fields rather than psychedelic psychiatry.
5
I found no reliable signal of local patient-access programmes, reimbursement routes or named psychedelic centres, so Blossom should treat Egypt as a medical-only, research-constrained jurisdiction.

Research Snapshot

Blossom currently tracks 3 psychedelic clinical trials connected to Egypt.

Active trials: 0
Total trials: 3
Stakeholders: 2
Events: 0

Top Compounds

Ketamine(3)

Medical Access Snapshot

Egypt maintains a highly restrictive national drug control regime with criminal penalties for unauthorized possession or use of narcotics and psychotropic substances; however, ketamine is an established, controlled medicinal anesthetic and is used in Egyptian hospitals and research settings. Other classic psychedelics (psilocybin, MDMA, DMT, 5-MeO-DMT, ibogaine, ayahuasca, mescaline, 2C-X) have no authorized medical market access outside approved clinical research and remain controlled under Egypt's narcotics/psychotropic laws.

View trials→View stakeholders→Open access guide→

Regulatory Status

Egypt's legal position is best characterised as highly restrictive: UNODC's country legislation materials show the anti-narcotics law prohibits unauthorised import, export, production, possession, handling, buying and selling of controlled substances, with UNODC also noting additional scheduling by ministerial decree. Ketamine is a controlled medicinal anaesthetic and may be used in hospitals and research settings, but I found no authoritative evidence of an authorised access pathway for psilocybin, MDMA, DMT, 5-MeO-DMT, ibogaine, ayahuasca, mescaline or 2C-X outside approved research. ([sherloc.unodc.org](https://sherloc.unodc.org/cld/fr/legislation/egy/loi_no._182_de_1960_sur_la_repression_du_trafic_des_substances_stupefiantes/chapitre_ix/articles_33-44/loi_182.html?utm_source=openai))